A Phase 1 study of pacritinib, venetoclax, and azacitidine in accelerated and blast phase myeloproliferative neoplasms
Not Yet Recruiting Phase 1 NCT07679334
Study Description
A study testing the safety and best dose of pacritinib combined with venetoclax and azacitidine in patients with advanced myeloproliferative neoplasms that have progressed to accelerated or blast phase
Study Details
- Registry ID:
- NCT07679334
- Conditions:
- Myeloproliferative Neoplasm
- Phase:
- Phase 1
- Target Enrollment:
- 20 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.